[go: up one dir, main page]

MX2009011898A - Composiciones y metodos para tratar trastornos asociados con retencion de sal o fluido. - Google Patents

Composiciones y metodos para tratar trastornos asociados con retencion de sal o fluido.

Info

Publication number
MX2009011898A
MX2009011898A MX2009011898A MX2009011898A MX2009011898A MX 2009011898 A MX2009011898 A MX 2009011898A MX 2009011898 A MX2009011898 A MX 2009011898A MX 2009011898 A MX2009011898 A MX 2009011898A MX 2009011898 A MX2009011898 A MX 2009011898A
Authority
MX
Mexico
Prior art keywords
methods
salt
compositions
disorders associated
fluid retention
Prior art date
Application number
MX2009011898A
Other languages
English (en)
Inventor
Mark G Currie
Daniel P Zimmer
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of MX2009011898A publication Critical patent/MX2009011898A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen métodos para reducir el riesgo de, o para tratar, un trastorno asociado con retención de fluido y/o sal en un paciente. Los métodos incluyen administrar al paciente un agente seleccionado de: a) un agente que reduce la absorción de sodio en el intestino; b) un agente que incrementa la secreción aniónica en el intestino; o c) un agente que reduce la absorción de sodio en el intestino e incrementa la secreción aniónica en el intestino.
MX2009011898A 2007-05-04 2008-04-23 Composiciones y metodos para tratar trastornos asociados con retencion de sal o fluido. MX2009011898A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91625707P 2007-05-04 2007-05-04
US98057307P 2007-10-17 2007-10-17
PCT/US2008/061205 WO2008137318A1 (en) 2007-05-04 2008-04-23 Compositions and methods for treating disorders associated with salt or fluid retention

Publications (1)

Publication Number Publication Date
MX2009011898A true MX2009011898A (es) 2009-11-18

Family

ID=39943889

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011898A MX2009011898A (es) 2007-05-04 2008-04-23 Composiciones y metodos para tratar trastornos asociados con retencion de sal o fluido.

Country Status (6)

Country Link
US (1) US20120040025A9 (es)
EP (2) EP2152266A4 (es)
CA (1) CA2686414A1 (es)
MX (1) MX2009011898A (es)
RU (1) RU2009144972A (es)
WO (1) WO2008137318A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2441970C (en) 2001-03-29 2013-01-22 Synergy Pharmaceuticals, Inc. Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
US7750124B2 (en) 2006-09-29 2010-07-06 Oncomed Pharmaceuticals, Inc. Anti-human DLL4 antibodies and compositions
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8034782B2 (en) 2008-07-16 2011-10-11 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) * 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
EP2296685B1 (en) * 2008-06-04 2015-09-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010040086A1 (en) * 2008-10-02 2010-04-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Administration of an adsorbent polymer for treatment of systemic inflammation
CA2743172A1 (en) 2008-11-19 2010-05-27 Forest Laboratories Holdings Limited Crystalline form of linaclotide
ES2608050T3 (es) * 2008-12-03 2017-04-05 Synergy Pharmaceuticals Inc. Formulaciones de agonistas de guanilato ciclasa C y métodos de uso
CA2748607A1 (en) 2008-12-31 2010-07-08 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10543207B2 (en) 2008-12-31 2020-01-28 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
EP2464373A1 (en) 2009-08-13 2012-06-20 Ironwood Pharmaceuticals, Inc. Method for modulating the pharmacodynamic effect of orally administered guanylate cyclase receptor agonists
ES2700450T3 (es) 2009-10-16 2019-02-15 Oncomed Pharm Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
JP6393037B2 (ja) 2010-09-15 2018-09-19 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃアゴニストの製剤および使用方法
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
ES2664873T3 (es) * 2011-03-01 2018-04-23 Synergy Pharmaceuticals Inc. Proceso de preparación de agonistas de guanilato ciclasa C
EP3485903B1 (en) 2011-09-23 2022-11-16 Mereo BioPharma 5, Inc. Vegf/dll4 binding agents and uses thereof
AU2013337811A1 (en) 2012-10-31 2015-05-14 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP3988120A1 (en) 2013-04-12 2022-04-27 Ardelyx, Inc. Nhe3-binding compounds and methods for inhibiting phosphate transport
US20160184387A1 (en) 2013-08-09 2016-06-30 Dominique Charmot Compounds and methods for inhibiting phosphate transport
US20160228403A1 (en) * 2013-10-04 2016-08-11 Tohoku University Agent for preventing or ameliorating renal dysfunction
ITMI20132065A1 (it) * 2013-12-11 2015-06-12 Farmatron Ltd Sistemi terapeutici a rilascio modificato per la somministrazione orale di curcumina nel trattamento delle malattie intestinali
WO2016076924A2 (en) * 2014-07-25 2016-05-19 Wake Forest University Fas inhibitors and methods associated therewith
MX382902B (es) 2014-10-31 2025-03-13 Oncomed Pharm Inc Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer.
WO2016130931A2 (en) * 2015-02-13 2016-08-18 The Johns Hopkins University Formulations of angiotensin receptor blockers
US10456404B2 (en) 2015-03-13 2019-10-29 Indiana University Research And Technology Corporation Targeting cGMP-related phosphodiesterases to reduce cyst formation in cystic kidney disease, and related materials and methods
CN105037177B (zh) * 2015-06-06 2017-03-08 青岛科技大学 一种超临界结晶法制备s‑美托洛尔的方法
WO2017053705A1 (en) 2015-09-23 2017-03-30 Oncomed Pharmaceuticals, Inc. Methods and compositions for treatment of cancer
CN110267944B (zh) 2017-01-09 2024-03-08 阿德利克斯股份有限公司 可用于治疗胃肠道病症的化合物
MX2019008171A (es) 2017-01-09 2020-02-05 Ardelyx Inc Inhibidores del antiporte mediado por nhe.
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport
JP7568380B2 (ja) * 2019-05-28 2024-10-16 トイメディカル株式会社 ナトリウム排出粒子
CN114206368A (zh) * 2019-05-31 2022-03-18 横向知识产权私人有限公司 肽及其用途
CN113512086B (zh) * 2021-08-20 2022-11-29 天津信谊津津药业有限公司 一种制备螺内酯中间体坎利酮的方法
US20250090573A1 (en) * 2022-01-18 2025-03-20 University Of Georgia Research Foundation, Inc. Compositions for delivering nitric oxide and fluoride and methods for making and using the same
CN115353551B (zh) * 2022-06-27 2024-01-26 上海理工大学 一种燕麦源促glp-1分泌寡肽及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020037279A1 (en) * 1996-09-13 2002-03-28 Herman H. Vandenburgh Delivery of bioactive compounds to an organism
JP3345650B2 (ja) * 1997-12-22 2002-11-18 日清食品株式会社 高血圧抑制剤
US20060281682A1 (en) * 2003-01-28 2006-12-14 Currie Mark G Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) * 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
RU2543350C2 (ru) * 2003-01-28 2015-02-27 Айронвуд Фармасьютикалз, Инк. Способы и композиции для лечения желудочно-кишечных расстройств
US7371727B2 (en) * 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JP2007523840A (ja) * 2003-04-30 2007-08-23 ワラタ ファーマシューティカルズ， インコーポレイテッド ケラチノサイト増殖因子アゴニストおよびカストリン化合物を組み合わせた使用
PL1644021T3 (pl) * 2003-06-13 2013-01-31 Ironwood Pharmaceuticals Inc Sposoby i kompozycje do leczenia zaburzeń żołądkowo-jelitowych
US7494979B2 (en) * 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
WO2005094384A2 (en) * 2004-03-30 2005-10-13 Ilypsa, Inc. Methods and compositions for treatment of ion imbalances
EP1996218A4 (en) * 2006-02-24 2012-07-11 Ironwood Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
US20120283411A9 (en) * 2006-06-29 2012-11-08 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP2129683A4 (en) * 2007-02-26 2011-01-05 Ironwood Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR TREATMENT OF HEART FAILURE AND OTHER DISORDERS
US20100310541A1 (en) * 2007-05-25 2010-12-09 Ironwood Pharmaceuticals, Inc. Compositions and Methods for Reducing the Toxicity of Certain Toxins

Also Published As

Publication number Publication date
WO2008137318A1 (en) 2008-11-13
EP2671584A3 (en) 2014-03-26
CA2686414A1 (en) 2008-11-13
EP2671584A2 (en) 2013-12-11
RU2009144972A (ru) 2011-06-10
EP2152266A4 (en) 2010-07-28
US20100215779A1 (en) 2010-08-26
US20120040025A9 (en) 2012-02-16
EP2152266A1 (en) 2010-02-17

Similar Documents

Publication Publication Date Title
MX2009011898A (es) Composiciones y metodos para tratar trastornos asociados con retencion de sal o fluido.
BRPI1011031A2 (pt) sal de arginina de um agente ativo, composição líquida ou em gel farmaceuticamente aceitável, kit, método para tratamento de uma desordem neurológica e método para tratar ou amenizar a doença de parkinson em um paciente que necessite deste.
TN2010000208A1 (en) Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
NZ700759A (en) Combination therapy for treating cancer
IN2015DN03219A (es)
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
EP2294184A4 (en) TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
PH12014500075A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MY166014A (en) Combination therapy methods for treating proliferative diseases
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2008122049A3 (en) Methods and compositions for reduction of side effects of therapeutic treatments
MX2020010004A (es) Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos.
UA103614C2 (uk) Лікарський засіб, що містить комбінацію інгібітора кінази та анти-гліпікан 3-антитіла, для лікування раку печінки
SG10201902664RA (en) Combination therapy for treating cancer
MX2014004548A (es) Metodos para tratar pacientes pediatricos usando dexmedetomidina.
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
NZ751816A (en) Pharmaceutical composition, methods for treating and uses thereof
MX353964B (es) Agentes terapeuticos y usos de los mismos.
MY153408A (en) Novel methods
MX348898B (es) Métodos y composiciones para tratar, reducir, o prevenir el deterioro del sistema visual de los animales.
BR112012027092A2 (pt) métodos e composiões para reduzir ou impedir a calcificação vascular durante a terapia de diálise peritoneal
SG10201810404XA (en) Combination comprising a glucocorticoid and edo-s101
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2009006574A (es) Tratamiento de cancer de pulmon.
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients

Legal Events

Date Code Title Description
FA Abandonment or withdrawal